Vanta Bioscience Limited

BSE: 540729
Vanta Bioscience Limited - pharma in Secunderabad, Telangana, India. FY 2026 financials & compliance.
CIN L74999TG2016PLC109280 Incorporated 29 April 2016 ROC Hyderabad HQ Secunderabad, Telangana, India
Active Listed - BSE: 540729 Public Limited Company pharma
Data last updated
Market Cap
₹13.91 Cr
VANTABIO · BSE
Share Price
₹19.56
0.00% today
Revenue
₹1.82 Cr
FY 2025-26 · -87.1% YoY
EBITDA
₹1.02 Cr
Margin 56.0%
Net Profit
₹0.10 Cr
FY 2025-26 · +9998.0% YoY
P/E (TTM)
135.2x
P/B 0.7x

About Vanta Bioscience Limited

Data last updated: 25 September 2026

Vanta Bioscience Limited is a public limited company based in Secunderabad, Telangana, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 29 April 2016, the company has been in operation for over 10 years.

Registered with ROC Hyderabad under CIN L74999TG2016PLC109280. Listed on BSE: 540729.

Capital: an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹7.11 Cr. Formerly known as Vanta Bioscience Private Limited. It is led by directors including Dopesh Raja Mulakala and Vyasmurti Madhavrao Shingatgeri.

Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: No.02/G/308/G No.3/Ff/Sf/1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1.82 Cr, a decline of 7.14% compared to the previous year.

The company has a workforce of approximately 43 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Vanta Bioscience. As per MCA filings, the company has open charges of ₹6.57 Cr and satisfied charges of ₹17 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vantabio.com.

Company Details of Vanta Bioscience Limited
CIN L74999TG2016PLC109280
Registration Number 109280
Incorporation Date 29 April 2016
ROC Hyderabad
Listing Status Listed (BSE: 540729)
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
Key People
Dopesh Raja Mulakala Managing Director Vyasmurti Madhavrao Shingatgeri Whole-Time Director Padmanabhuni Venkata Appaji Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    vantabio.com
  • Social Media
  • Registered Address
    No.02/G/308/G No.3/Ff/Sf/1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003
  • Industry
    Pharma, Pharma Contract R&D
Company report
Vanta Bioscience Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Vanta Bioscience Limited report

Financials, compliance, directors, charges, ownership and filings for Vanta Bioscience Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Vanta Bioscience Limited

Vanta Bioscience Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74999TG2016PLC109280, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74999TG2016PLC109280 Current
U74999TG2016PTC109280 Previous
U74999TG2016PLC109280 Previous

Associated Brands with Vanta Bioscience Limited

Vanta Bioscience Limited operates one associated brand: Vanta Bioscience. These brands represent Vanta Bioscience Limited's diversified market presence and brand portfolio.

Brand Description Website
Vanta Bioscience
GLP-certified preclinical contract research services are provided. vantabio.com

Competitors & Alternatives of Vanta Bioscience Limited

Brands and companies operating in the same space as Vanta Bioscience Limited include PHAXIAM, Gubra, BioQual and 6 more.

Competitor Description Location Founded
PHAXIAM PHAXIAM Antibacterial treatments using bacteriophages are developed for resistant infections. Lyon, France, France 2004
Gubra Gubra Preclinical CRO services for NAFLD/NASH, diabetes, and obesity are provided. Horsholm, Denmark, Denmark 2008
BioQual BioQual Contract research on infectious disease models is conducted. Rockville, United States, United States 1981
Tigermed Tigermed Drug development and preclinical services are provided by Tigermed. Hangzhou, China, China 2004
Gentronix Gentronix In-vitro and in-vivo genetic toxicology screening services are provided. Alderley Edge, United Kingdom, United Kingdom 1999
Aquila BioMedical Aquila BioMedical Preclinical services in immunology, regeneration, neuroscience, and histology are provided. Edinburgh, United Kingdom, United Kingdom 2011
ReveraGen ReveraGen Steroids for Duchenne muscular dystrophy treatment are developed. Rockville, United States, United States 2008
VGXI VGXI Contract developer and manufacturer of plasmids The Woodlands, United States, United States 1997
Shanghai Semero Biotechnology Shanghai Semero Biotechnology Diversified preclinical services for brain-related disorders are provided. Shanghai, China, China 2014

Business Activity of Vanta Bioscience Limited

Vanta Bioscience Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including architecture, engineering activities, technical testing and analysis activities.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M4 Architecture, engineering activities, technical testing and analysis activities Locked
Premium access

Business activity turnover details for Vanta Bioscience Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Vanta Bioscience Limited

Vanta Bioscience Limited is audited by Mathesh & Ramana for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Mathesh & Ramana Locked Locked Locked
Premium access

Complete auditor history for Vanta Bioscience Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Vanta Bioscience Limited

Vanta Bioscience Limited is currently managed by 5 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Dopesh Raja Mulakala
Also directs: Vanta Bioscience Limited, Sarvotham Care Limited, Shree Cosmetics Limited and 3 more
Managing Director 29 Apr 2016 10 Years 4 Months Current
Vyasmurti Madhavrao Shingatgeri
Also directs: Vanta Bioscience Limited, Spectrogen Pharmachem Limited
Whole-Time Director 08 Feb 2017 9 Years 7 Months Current
Padmanabhuni Venkata Appaji
Also directs: Vanta Bioscience Limited, Vasudha Pharma Chem Limited, Genphex Life Sciences Private Limited and 1 more
Director 20 Mar 2017 9 Years 6 Months Current
Gonuguntla Kathyayani
Also directs: Vanta Bioscience Limited, Vasudha Pharma Chem Limited
Director 19 May 2017 9 Years 4 Months Current
Yogeswara Rao Danda
Also directs: Vanta Bioscience Limited, Association For Scientific Pursuits For Innovative Research Enterprises, Nutrihub Technology Business Incubator Startups Confederation
Director 22 May 2019 7 Years 4 Months Current
View all directors

Financials of Vanta Bioscience Limited FY 2025-26 filings available

Vanta Bioscience Limited reported revenue of ₹1.82 Cr (down 7.14% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1.82 Cr
-7.1% YoY
EBITDA
₹1.02 Cr
+123.9% YoY
Profit After Tax
₹0.10 Cr
+102.1% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1.821.969.726.289.6910.0414.14
Revenue growth-87.1%-26.0%-3.1%+39.2%+2.3%-37.7%+6.8%
EBITDA1.02(4.26)1.32(2.39)3.463.954.37
EBITDA margin+56.0%-217.4%+13.6%-38.1%+35.7%+39.3%+30.9%
Profit before tax0.01(12.64)(8.82)(10.26)0.210.591.34
Net profit0.10(4.78)(2.35)(6.48)0.070.440.98
Net profit margin+5.5%-243.9%-24.2%-103.2%+0.7%+4.4%+6.9%
EPS (₹)0.15(7.56)(3.67)(10.27)0.140.711.59
Balance sheet
Total assets-73.8773.9376.0974.2162.2041.83
Net worth-10.4215.2017.5124.0123.9223.47
Total debt-70.0960.9657.1644.8635.9717.37
Cash & bank-0.220.160.100.222.650.20
Net working capital-4.766.447.608.0813.2213.70
Cash flow
Cash from operations-(2.41)2.68(0.63)5.286.972.34
Cash from investing-(6.69)(3.31)(5.91)(17.24)(22.30)(7.59)
Cash from financing-9.160.696.419.5317.782.17
ParticularsMar 2023Dec 2022Dec 2021
Revenue0.632.820.00
Revenue growth (YoY)+9997.0%+9997.0%+9997.0%
Other income0.670.010.00
EBITDA(1.30)(0.55)0.00
EBITDA margin-206.3%-19.5%-
Depreciation0.051.310.00
Interest0.922.480.00
Profit before tax(1.36)(2.47)0.38
Tax(0.01)0.090.38
Net profit(1.35)(2.56)0.00
EPS (₹)0.00(4.06)0.00
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1.821.138.565.179.3510.0414.11
Revenue growth-71.6%-43.4%-12.8%-5.4%-3.3%-37.2%+7.0%
EBITDA1.03(1.65)3.65(0.46)3.403.894.32
EBITDA margin+56.6%-146.0%+42.6%-8.9%+36.4%+38.8%+30.6%
Profit before tax0.02(2.71)0.04(4.19)0.140.601.29
Net profit0.11(2.65)0.01(4.22)0.080.460.96
Net profit margin+6.0%-234.5%+0.1%-81.6%+0.9%+4.6%+6.8%
EPS (₹)0.17(4.21)0.08(6.71)0.120.751.55
Balance sheet
Total assets-47.6045.1745.5044.7641.1937.59
Net worth-17.1319.7919.7423.9923.9123.44
Total debt-30.4725.3825.7620.7717.2814.15
Cash & bank-0.140.140.070.070.070.09
Net working capital-2.895.085.806.159.1714.08
Cash flow
Cash from operations-1.364.550.646.7011.013.17
Cash from investing-(5.79)(1.67)(2.53)(8.08)(9.96)(1.56)
Cash from financing-4.43(2.81)1.881.38(1.07)(1.80)
ParticularsMar 2023Dec 2022Dec 2021
Revenue1.761.710.00
Revenue growth (YoY)+9997.0%+9997.0%+9997.0%
Other income0.610.010.00
Total expenses2.881.380.00
EBITDA(1.12)0.330.00
EBITDA margin-63.6%+19.3%-
Depreciation0.000.620.00
Interest0.711.200.00
Profit before tax(1.22)(1.48)0.00
Tax0.000.010.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsMar 2023Dec 2022Dec 2021
Revenue0.632.820.00
Revenue growth (YoY)+9997.0%+9997.0%+9997.0%
Other income0.670.010.00
EBITDA(1.30)(0.55)0.00
EBITDA margin-206.3%-19.5%-
Depreciation0.051.310.00
Interest0.922.480.00
Profit before tax(1.36)(2.47)0.38
Tax(0.01)0.090.38
Net profit(1.35)(2.56)0.00
EPS (₹)0.00(4.06)0.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1.821.969.726.289.6910.0414.14
Revenue growth-87.1%-26.0%-3.1%+39.2%+2.3%-37.7%+6.8%
Other income0.160.110.110.690.420.030.11
Total expenses0.806.228.408.676.236.099.77
Employee cost0.001.763.793.462.672.513.93
EBITDA1.02(4.26)1.32(2.39)3.463.954.37
EBITDA margin+56.0%-217.4%+13.6%-38.1%+35.7%+39.3%+30.9%
Depreciation0.394.424.502.671.321.251.19
Interest0.784.075.755.892.352.141.95
Profit before tax0.01(12.64)(8.82)(10.26)0.210.591.34
Tax(0.09)0.66(0.22)0.180.090.140.33
Net profit0.10(4.78)(2.35)(6.48)0.070.440.98
Net profit margin+5.5%-243.9%-24.2%-103.2%+0.7%+4.4%+6.9%
EPS (₹)0.15(7.56)(3.67)(10.27)0.140.711.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-6.316.316.316.316.316.31
Reserves & surplus-4.118.8911.2017.7017.6117.16
Shareholders' funds (net worth)-10.4215.2017.5124.0123.9223.47
Minority interest-(6.64)(2.23)1.415.342.310.99
Secured loans-29.1834.6445.2836.8330.3716.27
Unsecured loans-40.9126.3211.888.035.601.10
Total debt-70.0960.9657.1644.8635.9717.37
Total liabilities-73.8773.9376.0974.2162.2041.83
Assets
Gross block-74.8768.7064.3741.1633.1123.23
Net block-55.5054.1657.2336.1229.3920.76
Capital work in progress-13.4712.5310.6028.4719.347.00
Investments-0.000.000.000.000.000.00
Inventories-6.517.527.167.249.7614.01
Sundry debtors-2.503.141.961.132.011.39
Cash & bank balances-0.220.160.100.222.650.20
Loans & advances-6.136.346.035.905.514.25
Total current assets-15.3617.1615.2514.4919.9319.85
Total current liabilities-10.6010.727.656.416.716.15
Net working capital-4.766.447.608.0813.2213.70
Total assets-73.8773.9376.0974.2162.2041.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.160.100.222.650.203.27
Net cash from operating activities-(2.41)2.68(0.63)5.286.972.34
Net cash from investing activities-(6.69)(3.31)(5.91)(17.24)(22.30)(7.59)
Net cash from financing activities-9.160.696.419.5317.782.17
Net change in cash-0.060.06(0.13)(2.43)2.46(3.07)
Closing cash-0.220.160.100.222.650.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.1%-79.8%+54.8%-35.2%-3.5%-29.0%+13.9%
EBITDA growth+9998.0%-+9998.0%--12.4%-9.6%+33.6%
PBT growth+9998.0%-43.3%+14.0%--64.4%-56.0%+21.8%
Net income growth+9998.0%-103.4%+63.7%--84.1%-55.1%+75.0%
Revenue CAGR (3Y)-33.8%-41.3%-1.1%-23.7%-7.9%--
EBITDA CAGR (3Y)---30.6%-+1.9%--
Profitability & leverage
Net income margin+5.5%-678.6%-88.5%-166.2%+1.2%+4.5%+7.1%
Return on capital employed-0.0%0.0%0.0%+4.0%+5.4%+8.6%
Return on net worth-0.0%0.0%0.0%+0.5%+1.9%+4.4%
Debt / equity-5.113.612.461.691.130.67
Long-term debt / equity-4.022.932.051.461.000.63
Interest cover123.81-46.89-180.82-116.40109.8179.2661.32
Efficiency & per share
Fixed asset turnover-0.030.150.120.260.360.67
Inventory turnover-0.281.320.871.140.841.22
Debtors turnover-0.703.814.066.175.919.59
EPS (₹)0.15(7.56)(3.67)(10.27)0.140.711.59
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0016.5124.0827.7538.0337.8937.18
ParticularsMar 2023Dec 2022Dec 2021
Revenue1.761.710.00
Revenue growth (YoY)+9997.0%+9997.0%+9997.0%
Other income0.610.010.00
Total expenses2.881.380.00
EBITDA(1.12)0.330.00
EBITDA margin-63.6%+19.3%-
Depreciation0.000.620.00
Interest0.711.200.00
Profit before tax(1.22)(1.48)0.00
Tax0.000.010.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1.821.138.565.179.3510.0414.11
Revenue growth-71.6%-43.4%-12.8%-5.4%-3.3%-37.2%+7.0%
Other income0.160.040.050.630.170.020.11
Total expenses0.792.784.915.635.956.159.79
Employee cost0.000.582.682.752.572.513.79
EBITDA1.03(1.65)3.65(0.46)3.403.894.32
EBITDA margin+56.6%-146.0%+42.6%-8.9%+36.4%+38.8%+30.6%
Depreciation0.390.441.241.251.321.251.19
Interest0.780.662.423.112.112.061.95
Profit before tax0.02(2.71)0.04(4.19)0.140.601.29
Tax(0.09)(0.06)(0.01)0.030.060.130.31
Net profit0.11(2.65)0.01(4.22)0.080.460.96
Net profit margin+6.0%-234.5%+0.1%-81.6%+0.9%+4.6%+6.8%
EPS (₹)0.17(4.21)0.08(6.71)0.120.751.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-6.316.316.316.316.316.31
Reserves & surplus-10.8213.4813.4317.6817.6017.13
Shareholders' funds (net worth)-17.1319.7919.7423.9923.9123.44
Secured loans-15.0616.8318.2417.2916.6813.55
Unsecured loans-15.418.557.523.480.600.60
Total debt-30.4725.3825.7620.7717.2814.15
Total liabilities-47.6045.1745.5044.7641.1937.59
Assets
Gross block-51.1345.3443.6941.1633.1123.23
Net block-42.4437.8837.4036.1229.3920.76
Capital work in progress-0.000.000.000.000.000.00
Investments-3.003.003.003.003.003.00
Inventories-6.487.487.167.249.7614.01
Sundry debtors-1.742.341.920.721.981.36
Cash & bank balances-0.140.140.070.070.070.09
Loans & advances-2.022.061.982.981.702.03
Total current assets-10.3812.0211.1311.0113.5117.49
Total current liabilities-7.496.945.334.864.343.41
Net working capital-2.895.085.806.159.1714.08
Total assets-47.6045.1745.5044.7641.1937.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.140.070.070.070.090.28
Net cash from operating activities-1.364.550.646.7011.013.17
Net cash from investing activities-(5.79)(1.67)(2.53)(8.08)(9.96)(1.56)
Net cash from financing activities-4.43(2.81)1.881.38(1.07)(1.80)
Net change in cash-0.000.070.000.00(0.02)(0.20)
Closing cash-0.140.140.070.070.070.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+61.1%-86.8%+65.6%-44.7%-6.9%-28.8%+13.6%
EBITDA growth+9998.0%-+9998.0%--12.6%-10.0%+32.1%
PBT growth+9998.0%-+9998.0%--76.7%-53.5%+17.3%
Net income growth+9998.0%-+9998.0%--82.6%-52.1%+71.4%
Revenue CAGR (3Y)-29.4%-50.6%-5.2%-28.4%-9.0%+36.0%-
EBITDA CAGR (3Y)---2.1%-+1.3%+55.7%-
Profitability & leverage
Net income margin+6.0%-234.5%+0.6%-81.6%+0.9%+4.7%+7.0%
Return on capital employed-0.0%+5.2%0.0%+5.2%+6.8%+8.9%
Return on net worth-0.0%+0.1%0.0%+0.3%+2.0%+4.3%
Debt / equity-1.511.291.060.790.660.60
Long-term debt / equity-1.020.990.830.550.490.56
Interest cover121.88-31.58100.41-181.87101.4478.0362.30
Efficiency & per share
Fixed asset turnover-0.020.190.120.250.360.67
Inventory turnover-0.161.170.721.100.841.21
Debtors turnover-0.554.023.926.936.019.66
EPS (₹)0.17(4.21)0.08(6.71)0.120.751.55
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0027.1431.3631.2838.0137.8837.14
Want more history and ratios?
You're viewing the latest exchange-filed financials for Vanta Bioscience Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Vanta Bioscience Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 72.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 27.20% of Vanta Bioscience Limited.

Promoters: 72.80%Retail & Others: 27.20%
Jun 2026
QUARTER
72.80% Promoters
27.20% Retail & Others
Promoter holding - history
Now 72.80% · Jun 2026High 72.80% · Mar 2026Low 69.40% · Dec 2025
68%69.5%71%72.5%74%Dec 2025Mar 2026Jun 2026Dec 2025: 69.40%Mar 2026: 72.80%Jun 2026: 72.80%72.80%69.40%72.80%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025
Promoters72.80%72.80%69.40%
Public27.20%27.20%30.60%

Group Structure of Vanta Bioscience Limited

Vanta Bioscience Limited has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Vanta Bioscience Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
1
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Vanta Clinical Research Limited U73100TG2018PLC126673 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Vanta Bioscience Limited

Open charges
₹6.57 Cr
Satisfied charges
₹17 Cr
Breakdown by lending institutions
State Bank of India₹6.57 Cr
Latest charge details
DateLenderAmountStatus
27 Mar 2017 State Bank of India ₹6.57 Cr Open
03 Dec 2019 Axis Bank Limited ₹17 Cr Satisfied

Total charge records: 2 View all charges

Employees and EPFO Compliance at Vanta Bioscience Limited

Vanta Bioscience Limited has a workforce of 43 employees as of Mar 22, 2024.

Employee count
43
Active EPFO establishments
1
Employee growth
-8.51%
Premium access

Employee and EPFO history for Vanta Bioscience Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Vanta Bioscience Limited

Premium access

GST registrations and filing compliance for Vanta Bioscience Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Vanta Bioscience Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Vanta Bioscience Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Vanta Bioscience Limited

Premium access

MSME payment history for Vanta Bioscience Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Vanta Bioscience Limited

Premium access

Corporate group structure for Vanta Bioscience Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Vanta Bioscience Limited

Premium access

MCA filings and documents for Vanta Bioscience Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Vanta Bioscience Limited

Charges
26 May 2026
A charge with State Bank Of India of Rs. 6.57 Cr registered on 27 Mar 2017 with Charge ID 100092316 was modified on 26 May 2026.
Activity
30 Sep 2024
Vanta Bioscience Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Activity
31 Mar 2024
Vanta Bioscience Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Charges
26 Sep 2023
A charge registered on 03 Dec 2019 via Charge ID 100311514 with Axis Bank Limited was fully satisfied on 26 Sep 2023.
Directors
15 Sep 2022
Vidisha Vimal Hingu was appointed as a Company Secretary on 15 Sep 2022 & has been associated with this company since 4 years 11 days.
Directors
11 Nov 2021
Venkata Sathya Murali Dokka was appointed as a CFO on 11 Nov 2021 & has been associated with this company since 4 years 10 months.

Recent News on Vanta Bioscience Limited

Frequently Asked Questions about Vanta Bioscience Limited

Vanta Bioscience Limited is an active public limited company in the pharma sector based in Secunderabad, Telangana, India. It was incorporated on 29 April 2016 (10+ years old) and is registered under CIN L74999TG2016PLC109280. Listed on BSE: 540729. The company has 43 employees.

Vanta Bioscience Limited reported revenue of ₹1.82 Cr for FY 2025-26 (down 7.14% YoY) based on consolidated financials.

The current directors of Vanta Bioscience Limited are:

The primary industry of Vanta Bioscience Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.

Yes. Vanta Bioscience Limited is listed on BSE with code 540729.

Vanta Bioscience Limited can be reached at the registered office: No.02G308G No.3FfSf1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003, or through the website vantabio.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available